Piperacetazine

Piperacetazine is an orally active dopamine receptor antagonist and phenothiazine antipsychotic. Piperacetazine can directly bind to the PAX3::FOXO1 fusion protein and inhibit its transcriptional activity. Piperacetazine also exhibits antitumor activity with an IC50 of 7.627 μM against PANC-1 cells. Piperacetazine can be used for the research of diseases such as schizophrenia and pancreatic cancer and other tumors[1][2][3].

Product Specifications

CAS Number

[3819-00-9]

UNSPSC

12352005

Hazard Statement

H317

Target

CD276/B7-H3; Dopamine Receptor; FOXO

Type

Reference compound

Related Pathways

GPCR/G Protein; Immunology/Inflammation; Metabolic Enzyme/Protease; Neuronal Signaling

Applications

Neuroscience-Neuromodulation

Field of Research

Cancer; Neurological Disease

Assay Protocol

https://www.medchemexpress.com/Piperacetazine.html

Purity

98.03

Solubility

DMSO : ≥ 6 mg/mL|Ethanol : 50 mg/mL (ultrasonic)

Smiles

CC(C(C=C1N2CCCN3CCC(CCO)CC3)=CC=C1SC4=C2C=CC=C4)=O

Molecular Formula

C24H30N2O2S

Molecular Weight

410.57

Precautions

H317

References & Citations

[1]WEAVER LC, et al. Toxicopathologic and pharmacologic properties of piperacetazine, a potent tranquilizing agent. Toxicol Appl Pharmacol. 1963 Jan;5:49-60.|[2]Nakazawa K, et al. Piperacetazine Directly Binds to the PAX3::FOXO1 Fusion Protein and Inhibits Its Transcriptional Activity. Cancer Res Commun. 2023 Oct 6;3 (10) :2030-2043.|[3]Deng J, et al. Identification of an autophagy-related gene signature for predicting prognosis and immune activity in pancreatic adenocarcinoma. Sci Rep. 2022 Apr 29;12 (1) :7006.